These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 7585540)

  • 1. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
    Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
    Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
    Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
    Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
    Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
    Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein A potentiates lymphokine-activated killer cell induction in normal and melanoma patient lymphocytes.
    Singh KP; Shau H; Gupta RK; Kopald K; Ray PK
    Immunopharmacol Immunotoxicol; 1992; 14(1-2):73-103. PubMed ID: 1597662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
    Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B
    Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
    Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
    Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures.
    Spits H; Yssel H; Paliard X; Kastelein R; Figdor C; de Vries JE
    J Immunol; 1988 Jul; 141(1):29-36. PubMed ID: 2454260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effect of interleukin 10 on interleukin 12- and interleukin 2-mediated killer induction from blood mononuclear cells.
    Pai K; Yanagawa H; Takauchi E; Suzuki Y; Hanibuchi M; Parajuli P; Sone S
    Oncol Res; 1998; 10(6):295-300. PubMed ID: 9848100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.
    Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL
    Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures.
    Topalian SL; Kasid A; Rosenberg SA
    J Immunol; 1990 Jun; 144(11):4487-95. PubMed ID: 2160503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
    Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
    J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor recognition and lytic competence of IL-2-activated lymphocytes: regulation of both antibody-independent and -dependent cellular cytotoxicity via P75 IL-2 receptor.
    Lagoo-Deenadayalan S; Lagoo AS; Hardy KJ; Grimm EA
    Lymphokine Cytokine Res; 1992 Aug; 11(4):207-13. PubMed ID: 1420599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
    Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
    Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
    Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.